# Anti-HIV Immunoglobulin (HIVIG) in Prevention of Maternal-Fetal HIV Transmission (Pediatric ACTG Protocol 185)

> **NCT00000590** · PHASE3 · COMPLETED · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)**

## Conditions studied

- Acquired Immunodeficiency Syndrome
- Disease Transmission, Vertical
- HIV Infections

## Interventions

- **DRUG:** immunoglobulins

## Key facts

- **NCT ID:** NCT00000590
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1991-09
- **Primary completion:** —
- **Final completion:** 1996-12
- **Target enrollment:** — (—)
- **Last updated:** 2016-04-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00000590

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00000590, "Anti-HIV Immunoglobulin (HIVIG) in Prevention of Maternal-Fetal HIV Transmission (Pediatric ACTG Protocol 185)". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT00000590. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*